Details

Autor(en) / Beteiligte

• Blatt, Joseph A., MD
• Poole, Jeanne E., MD
• Johnson, George W., BSEE
• Callans, David J., MD
• Raitt, Merritt H., MD
• Reddy, Ramakota K., MD
• Marchlinski, Francis E., MD
• Yee, Raymond, MD
• Guarnieri, Thomas, MD
• Talajic, Mario, MD
• Wilber, David J., MD
• Anderson, Jill, RN
• Chung, Kiyon, MD, MPH
• Wong, Wai Shun, MD
• Mark, Daniel B., MD
• Lee, Kerry L., PhD
• Bardy, Gust H., MD

Titel

No Benefit From Defibrillation Threshold Testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)

Ist Teil von

• Journal of the American College of Cardiology, 2008-08, Vol.52 (7), p.551-556

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• No Benefit From Defibrillation Threshold Testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) Joseph A. Blatt, Jeanne E. Poole, George W. Johnson, David J. Callans, Merritt H. Raitt, Ramakota K. Reddy, Francis E. Marchlinski, Raymond Yee, Thomas Guarnieri, Mario Talajic, David J. Wilber, Jill Anderson, Kiyon Chung, Wai Shun Wong, Daniel B. Mark, Kerry L. Lee, Gust H. Bardy, for the SCD-HeFT Investigators Defibrillation testing is often performed during insertion of implantable cardioverter-defibrillators (ICDs) to confirm shock efficacy without good prospective data to suggest that this procedure improves outcomes. Our analysis included patients in the ICD arm of the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). We concluded that: 1) low baseline defibrillation thresholds (DFTs) were obtained in patients with optimally treated heart failure during ICD implantation for primary prevention of sudden death; 2) first shock efficacy for clinical ventricular tachyarrhythmias was high regardless of baseline DFT; and 3) baseline DFT did not predict long-term mortality or shock efficacy.